BUZZ-Cassava falls after stopping development of Alzheimer's drug

Reuters2025-03-25

** Shares of drug developer Cassava Sciences SAVA.O fall 21.4% to $2.20 premarket

** SAVA says it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, by the end of Q2

** In trials, the drug failed to significantly reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo

** In November, co said it would stop all trials of the drug

** The drug has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June

** Stock fell 89.4% since Nov 2024

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522713660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522713660","market":"nz","top_or_hot":-1,"title":"BUZZ-Cassava falls after stopping development of Alzheimer's drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cassava falls after stopping development of Alzheimer's drug</title></head><body><p>** Shares of drug developer Cassava Sciences <span>SAVA.O</span> fall 21.4% to $2.20 premarket</p><p>** SAVA <span>says</span> it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, <span>by the end of Q2</span></p><p>** In <span>trials</span>, the drug failed to <span>significantly </span>reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo</p><p>** In November, co said it would stop all trials of the drug</p><p>** The drug has been at the center of scrutiny after a medical professor <span>linked</span> to its development was charged with fraud in June</p><p>** Stock fell 89.4% since Nov 2024</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cassava falls after stopping development of Alzheimer's drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cassava falls after stopping development of Alzheimer's drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-25 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cassava falls after stopping development of Alzheimer's drug</title></head><body><p>** Shares of drug developer Cassava Sciences <span>SAVA.O</span> fall 21.4% to $2.20 premarket</p><p>** SAVA <span>says</span> it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, <span>by the end of Q2</span></p><p>** In <span>trials</span>, the drug failed to <span>significantly </span>reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo</p><p>** In November, co said it would stop all trials of the drug</p><p>** The drug has been at the center of scrutiny after a medical professor <span>linked</span> to its development was charged with fraud in June</p><p>** Stock fell 89.4% since Nov 2024</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80UF:1","article_id":"2522713660","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522713660","pubTimestamp":1742908631,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Cassava falls after stopping development of Alzheimer's drug** Shares of drug developer Cassava Sciences SAVA.O fall 21.4% to $2.20 premarket** SAVA says it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, by the end of Q2** In trials, the drug failed to significantly reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo** In November, co said it would stop all trials of the drug** The drug has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June** Stock fell 89.4% since Nov 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","SAVA":"Cassava Sciences Inc","BK4007":"制药","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念"},"translate_title":"BUZZ-Cassava停止阿尔茨海默氏症药物开发后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9},"content_text":"BUZZ-Cassava falls after stopping development of Alzheimer's drug** Shares of drug developer Cassava Sciences SAVA.O fall 21.4% to $2.20 premarket** SAVA says it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, by the end of Q2** In trials, the drug failed to significantly reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo** In November, co said it would stop all trials of the drug** The drug has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June** Stock fell 89.4% since Nov 2024 (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522713660","isCrawlerRequest":true}